Acute Promyelocytic Leukemia – A Review of the Literature

Acute Promyelocytic Leukemia (APL) accounts for 10-15% of all acute myeloid leukemias. The treatment of low to intermediate risk patients have been largely successful using All-Trans Retinoic Acid/Arsenic Trioxide (ATRA/ATO) combination therapy. However, high-risk patients have a greater propensity to relapse as well as develop resistance to both ATRA and ATO.